Related Experiment Video
Updated: Nov 20, 2025

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts
Published on: February 23, 2024
Bergenin Attenuates Hepatic Fibrosis by Regulating Autophagy Mediated by the PPAR-γ/TGF-β Pathway
Yujing Xia1, Jingjing Li1, Kan Chen1
1Department of Gastroenterology, Shanghai Tenth People's Hospital, School of Clinical Medicine of Nanjing Medical University, Shanghai 200072, China.
Abstract:
Liver fibrosis is a pathological process involving diffuse extracellular matrix (ECM) deposition in the liver. It is typical of many chronic liver diseases, including cirrhosis, and effective drugs are needed. In this study, we explored the protective effect of bergenin on liver fibrosis induced by carbon tetrachloride and bile duct ligation. A variety of molecular biological methods (qRT-PCR, western blotting, and immunohistochemistry) were employed to confirm the increased degree of hepatocyte injury and ECM formation in the disease model, consistent with autophagy and activation of the TGF-β pathway. Bergenin activated PPAR-γ and inhibited TGF-β and autophagy and decreased liver fibrosis by inhibiting hepatocyte necrosis and ECM formation in a dose-dependent manner. The results suggest that bergenin may be a promising drug candidate for the treatment of liver fibrosis.
Insights
Bergenin shows promise for treating liver fibrosis by reducing liver injury and extracellular matrix deposition. This study found bergenin effectively inhibited key fibrotic pathways and autophagy.
Area of Science:
- Hepatology and Pharmacology
- Molecular Biology
Background:
- Liver fibrosis, characterized by excessive extracellular matrix (ECM) deposition, is a hallmark of chronic liver diseases like cirrhosis.
- Current treatments for liver fibrosis are limited, necessitating the development of novel therapeutic agents.
Purpose of the Study:
- To investigate the potential protective effects of bergenin against liver fibrosis induced by carbon tetrachloride and bile duct ligation.
- To elucidate the molecular mechanisms underlying bergenin's action on liver fibrosis, including its impact on autophagy and the TGF-β pathway.
Main Methods:
- Induction of liver fibrosis models using carbon tetrachloride and bile duct ligation in relevant study subjects.
- Quantitative real-time PCR (qRT-PCR), western blotting, and immunohistochemistry were utilized to assess hepatocyte injury and ECM formation.
- Analysis of autophagy markers and the transforming growth factor-beta (TGF-β) signaling pathway.
Main Results:
- Bergenin demonstrated a dose-dependent reduction in hepatocyte injury and ECM accumulation in the induced liver fibrosis models.
- Bergenin treatment led to the activation of peroxisome proliferator-activated receptor-gamma (PPAR-γ).
- Bergenin effectively inhibited the TGF-β pathway and autophagy, key contributors to liver fibrosis progression.
Conclusions:
- Bergenin exhibits significant hepatoprotective effects against induced liver fibrosis.
- The mechanism involves the activation of PPAR-γ, inhibition of the TGF-β pathway, and suppression of autophagy.
- Bergenin represents a potential therapeutic candidate for managing liver fibrosis and related chronic liver diseases.
Related Concept Videos
TGF - β Signaling Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
PI3K/mTOR/AKT Signaling Pathway
Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...

